ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - ITeos Therapeutics ( NASDAQ:ITOS )
NEW YORK and NEW ORLEANS, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ( "KSF" ) are investigating the proposed sale of iTeos Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025 - Titan Pharma ( NASDAQ:TTNP ) , ITeos Therapeutics ( NASDAQ:ITOS )
NEW YORK, July 31, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, SPTN on Behalf of Shareholders - SpartanNash ( NASDAQ:SPTN ) , ITeos Therapeutics ( NASDAQ:ITOS )
NEW YORK, July 30, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders - Olo ( NYSE:OLO ) , ITeos Therapeutics ( NASDAQ:ITOS )
NEW YORK, July 23, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - ZimVie ( NASDAQ:ZIMV ) , ITeos Therapeutics ( NASDAQ:ITOS )
NEW YORK, July 21, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc.
Vor Bio Appoints Biotech Industry Leaders Alexander ( Bo ) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Vor Biopharma ( NASDAQ:VOR )
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( "iTeos" ) ITOS today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ( "Concentra" ) will acquire iTeos for $10.047 in cash per share of ...
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( "iTeos" ) ( Nasdaq: ITOS ) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ( "Concentra" ) will acquire iTeos for $10.047 in cash per ...
e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies ...
iTeos Therapeutics ( ITOS ) Upgraded to Buy: Here's What You Should Know
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's session following better-than-expected quarterly results. Heico reported quarterly earnings of $1.12 per share which beat the analyst ...
iTeos Therapeutics Announces Its Intention to Wind Down Operations
- Board of Directors intends to cease operations ...
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Lavoro ( NASDAQ:LVRO ) , ITeos Therapeutics ( NASDAQ:ITOS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Philippe Houchois downgraded the rating for Rivian Automotive, Inc.
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Annexon ( NASDAQ:ANNX ) , Camtek ( NASDAQ:CAMT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut Annexon, Inc. ANNX price target from $20 to $14.
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile - ITeos Therapeutics ( NASDAQ:ITOS )
GALAXIES Lung-201 trial showed ORR benefit but failed to meet PFS criteria for belrestotug combo vs. monotherapy. iTeos holds $624.3 million in cash as of March 31, 2025, with a projected runway extending into 2027.
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival ...
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics ( ITOS ) : Can the Stock Really Move This High?
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in ...
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the ...
Wall Street Analysts Think iTeos Therapeutics ( ITOS ) Could Surge 212.5%: Read This Before Placing a Bet
The consensus price target hints at a 212.5% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About iTeos Therapeutics ( ITOS ) Rating Upgrade to Buy
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - ITeos Therapeutics ( NASDAQ:ITOS )
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate ( ORR ) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose ( RP2D ) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, ...
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate ( ORR ) and a median PFS of 7.7 months for all evaluable patients across the cohorts- Recommended Phase 2 dose ( RP2D ) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, ...
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that ...
iTeos to Participate in Upcoming Investor Conferences - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ITOS, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management ...
e-therapeutics Announces Business Updates and Interim Results
LONDON, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business updates, including its unaudited interim results for the six months to 31st July 2024.
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
Crude Oil Surges Over 1%; Instil Bio Shares Plunge - NuCana ( NASDAQ:NCNA )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday. The Dow traded up 0.29% to 41,512.19 while the NASDAQ fell 0.96% to 17,514.54. The S&P 500 also fell, dropping, 0.24% to 5,612.35. In trading on Monday, information technology shares fell by ...
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ITeos Therapeutics ( NASDAQ:ITOS )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos Therapeutics, Inc. ITOS fell sharply in today's pre-market trading. The company announced follow-up interim data from GALAXIES Lung-201.
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Exicure ( NASDAQ:XCUR )
Shares of Exicure, Inc. XCUR rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Exicure shares jumped 49.3% to $2.39 in the pre-market trading. Here are some other stocks moving in pre-market trading.
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- Clinically meaningful objective response rate ( ORR ) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR ( cORR ) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety ...
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Strasbourg, France, September 10, 2024, 7 : 30 AM CET - Transgene TNG, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of two seasoned leaders in oncology who will be instrumental in advancing the ...
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Newly appointed CMO, Dr. Emmanuelle Dochy, and newly appointed CSO, Dr. Maurizio Ceppi, bring a strong track record of advancing cancer immunotherapies and precision medicine through clinical development as Transgene progresses its innovative preclinical and clinical pipeline including ...
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
ITeos Therapeutics, Inc. ( ITOS ) Reports Q2 Loss, Tops Revenue Estimates
iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ITOS ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the ...
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer - ITeos Therapeutics ( NASDAQ:ITOS )
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc.
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 ( GLOBE NEWSWIRE ) -- iTeos Therapeutics, Inc. ( Nasdaq: ITOS ) ( "iTeos" ) , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its ...
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday - Groupon ( NASDAQ:GRPN )
U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday. Shares of Genpact Limited G rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings - Dnow ( NYSE:DNOW ) , Evolv Technologies ( NASDAQ:EVLV )
U.S. stocks traded higher this morning, with the Dow Jones index jumping over 100 points on Friday. Following the market opening Friday, the Dow traded up 0.33% to 39,516.53 while the NASDAQ rose 0.43% to 16,416.55. The S&P 500 also rose, gaining, 0.38% to 5,233.70.
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy- GSK to provide update on ...
iTeos Therapeutics Announces $120 Million Registered Direct Offering
- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma cash position of $715 million, extending anticipated runway through ...
